New hope for Tough-to-Treat colon cancer patients
NCT ID NCT06634875
Summary
This study is testing whether adding a new immunotherapy drug called isunakinra to an existing cancer drug (pembrolizumab) can help control advanced colorectal cancer that has spread or cannot be surgically removed. The trial is for patients whose cancer has specific genetic features and who have already tried other standard treatments. Researchers want to see if this combination can slow cancer growth in patients who typically don't respond well to current immunotherapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hoag Memorial Hospital Presbyterian
RECRUITINGNewport Beach, California, 92658, United States
-
USC/Norris Cancer Center
RECRUITINGLos Angeles, California, 90089, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.